SCHEMBL5633809

SCHEMBL5633809

CCCCN1C(=O)C(=C(N)N)C(=O)N(CCCCCc2ccccc2)C1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
GSK3A P49840 2/20 0.50
GSK3B P49841 2/20 0.50
MAPT P10636 2/20 0.49
MEN1 O00255 1/20 0.49
USP2 O75604 1/20 0.49
CYP1A2 P05177 1/20 0.49
POLB P06746 1/20 0.49
CYP3A4 P08684 1/20 0.49
THRB P10828 1/20 0.49
CYP2C9 P11712 1/20 0.49
HPGD P15428 1/20 0.49
ALOX12 P18054 1/20 0.49
CYP2C19 P33261 1/20 0.49
RECQL P46063 1/20 0.49
BLM P54132 1/20 0.49
KMT2A Q03164 1/20 0.49
FAAH O00519 1/20 0.48
MGLL Q99685 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5633937 0.99 TDP1 (0.54) TDP1L3MBTL1GSK3AGSK3BMAPT
SCHEMBL5633422 0.82 MAPT (0.43) TDP1L3MBTL1MAPTMEN1USP2
SCHEMBL5442584 0.77 MAPT (0.67) TDP1L3MBTL1GSK3AGSK3BMAPT
SCHEMBL5633577 0.76 HTT (0.49) L3MBTL1MAPTKMT2AFAAH
SCHEMBL5634864 0.75 TDP1 (0.50) TDP1L3MBTL1GSK3AGSK3BMAPT
SCHEMBL14560436 0.74 KMT2A (0.59) TDP1L3MBTL1MAPTMEN1USP2
SCHEMBL5632662 0.73 L3MBTL1 (0.48) TDP1L3MBTL1GSK3AGSK3BMAPT
SCHEMBL14560433 0.73 ELANE (0.58) TDP1L3MBTL1MAPTMEN1USP2
SCHEMBL5093425 0.73 TDP1 (1.00) TDP1L3MBTL1GSK3AGSK3BFAAH
SCHEMBL9219707 0.73 TDP1 (1.00) TDP1L3MBTL1GSK3AGSK3BFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070123548-A1 Pth agonists COWAN DAVID J 2007-05-31 US claimed
US-20070123548-A1 Pth agonists COWAN DAVID J 2007-05-31 US disclosed
EP-1713782-A1 PTH AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2006-10-25 EP disclosed
WO-2005077918-A1 PTH AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070123548-A1 Pth agonists PTH1R, SSTR3, CALCR TDP1 4833/4885L3MBTL1 4667/4885GSK3A 3239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.